Contineum Therapeutics, Inc. (CTNM): Operating Income

Annual figures by period end, from SEC filings.

-$68.06M

Year ended 2025-12-31

-$66.38M

Trailing 12 months to 2026-06-30

2023-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$68.06M	n/m	2026-03-05, From 2025-01-01
2024-12-31	-$50.89M	n/m	2026-03-05, From 2024-01-01
2023-12-31	$16.08M	n/a	2025-03-06, From 2023-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Contineum Therapeutics, Inc. (CTNM)	2025-12-31	-$68.06M	n/m
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	-$125.70M	n/m
Annexon, Inc. (ANNX)	2025-12-31	-$216.41M	n/m
Altimmune, Inc. (ALT)	2025-12-31	-$94.49M	n/m
Nektar Therapeutics (NKTR)	2025-12-31	-$140.10M	n/m
Enanta Pharmaceuticals Inc (ENTA)	2025-09-30	-$85.35M	n/m
Arcturus Therapeutics Holdings Inc. (ARCT)	2025-12-31	-$76.26M	n/m
Tyra Biosciences, Inc. (TYRA)	2025-12-31	-$132.76M	n/m
Zevra Therapeutics, Inc. (ZVRA)	2025-12-31	-$62.94M	n/m

Compare CTNM, TNXP, ANNX, ALT side by side · Screen every company in Pharmaceutical Preparations ↗